WEGO Corporate and Strategy Overview
Key financials
Revenue 3 (RMBmm)
Growth (%)
17.7%
10,364
8,809
2018
2019
9.5%
2018-2022 CAGR: 11.5%
11,345
2020
EBITDA 1,2,3,5 (RMBmm)
EBITDA margin(%)
31.5%
31.3%
29.3%
Operating profit 1,3,4 (RMBmm)
Operating profit margin (%)
15.9%
3.6%
18.0%
19.9%
19.9%
21.8%
23.0%
13,152
13,619
2021
2022
30.8%
30.7%
2018-2022 CAGR: 10.8%
4,051
4,183
3,247
3,322
2,773
2018-2022 CAGR: 18.5%
2,866
3,128
2,066
2,255
1,586
2018
2019
2020
2021
2022
Net profit attributable to owners of the Company 1,2,3,5 (RMBmm)
Net margin (%)
18.7%
19.4%
19.0%
19.8%
21.5%
2018-2022 CAGR: 14.7%
2,743
2,408
1,923
2,030
1,587
2018
2019
2021
2022
2018
2019
2020
2021
2022
2
2020
Notes: 1 After deduction of special items such as inventory appreciation due to the acquisition of Argon Medical in 2018 and the one-time transaction fee of the acquisition;
After deduction of special item of the one-time debt replacement fee of Argon Medical in 2019; 3 Not including the impact of accounting restatement of business under the
same control in 2019, 2020 and 2021; 4 Operating profit refers to the total pre-tax profit of each segment; 5 After deduction of accrual litigation expense in 2021 as well as the
deduction of dilution of Group's interest in WEGO Blood Purification, after-tax income recorded from land and housing recycled by government and after-tax expense for
WEGO product liability claims in 2022.
The above figures are only for the purpose of reflecting the trend at the operational level of the Company. The specific figures are subject to performance reports.
17View entire presentation